Apellis Pharmaceuticals Inc

APLS

Equity

ISIN US03753U1060 / Valor 30132056

NASDAQ (2024-11-20)

USD 27.49-5.17%

Apellis Pharmaceuticals Inc
UMushroom community rating:

3.00 1 votes No rating yet

NegativeNeutralPositive

About company

Apellis Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies to treat a range of debilitating diseases by targeting the complement cascade, a key component of the immune system. The company has pioneered the first new class of complement medicine in over a decade, with two approved treatments that focus on C3, the central protein in the complement cascade. This includes the groundbreaking therapy for geographic atrophy, a major cause of blindness worldwide. Founded by a group of post-doctoral scientists in Kentucky, Apellis has grown on the strength of its innovative scientific approach and commitment to addressing significant unmet medical needs. The company's pipeline includes nearly a dozen clinical and pre-clinical programs aimed at exploiting the therapeutic potential of targeting C3 in various serious diseases.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-44.5%1Y

-37.4%3Y

-4.22%5Y

Performance

59.4%1Y

71.9%3Y

73.6%5Y

Volatility